|Last Update: 05/24/13 - 4:00 PM EDT|
|YTD Performance: 10.99%|
|Previous Close: $54.74|
|52 Week Range: $39.93 - $58.41|
|Oustanding Shares: 1,126,561,464|
|Market Cap: 61,870,755,603|
|Qtr (06/13)||Qtr (09/13)||FY (12/13)||FY (12/14)|
|Number of Analysts||8||7||12||10|
|Growth Rate (Year over Year)||21.08%||19.35%||15.39%||-29.67%|
Shares of LLY now seen reaching $60, Citigroup said. Estimates also increased as stronger base undervalues Ramucirumab call option. Buy rating.
Our primary area of interest this morning will be the 1494.50 level.
Not so much by the financials.
LLY was initiated with a Buy rating, Citigroup said. $55 price target. Sequestration risk to Medicare part D drugs spend small.
Credit Suisse Group AG Healthcare Conference
Shares of LLY now seen reaching $47, BMO said. Estimates also lowered on cautious outlook on Sola. Market Perform rating.
It’s been a thoroughly boring, commonsense rally.
Shares of LLY now seen reaching $57, according to Bank of America/Merrill Lynch said. Sola should ultimately reach the market for Alzheimer's. Buy rating.
LLY was upgraded from Sell to Neutral, Goldman Sachs said. $54 price target. Sola could reach the market in 3 to 4 years.
Shares of LLY now seen reaching $54, according to Credit Suisse. Estimates also increased, given higher expected Ramucirumab sales. Outperform rating.